Trial Profile
A Phase I, Single Dose, Open-Label Study Comparing the Pharmacokinetics and Safety of Pretomanid in Subjects With Mild, Moderate, and Severe Hepatic Impairment to Matched, Non-Hepatically Impaired Subjects
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 01 Jan 2024
Price :
$35
*
At a glance
- Drugs Pretomanid (Primary)
- Indications Tuberculosis
- Focus Pharmacokinetics
- 21 Dec 2023 Status changed from recruiting to discontinued.
- 21 Oct 2022 Planned End Date changed from 31 Aug 2022 to 31 Aug 2023.
- 21 Oct 2022 Planned primary completion date changed from 31 Aug 2022 to 31 Aug 2023.